Drais Pharmaceuticals, Inc. Information

Drais Pharmaceuticals, Inc. is a venture capital supported drug development company with an exciting new business model. Through strong relationships with Astellas Pharma Inc. and our venture capital investors - InterWest Partners, Sutter Hill Ventures, and Astellas Venture Management LLC, we have created multiple virtual companies to enable the development of interesting novel compounds in a variety of therapeutic areas. Our focus is on early stage development through proof of concept. Our business model relies on a small internal team who provide drug development services to those virtual companies via vendors and CROs. Our internal experts are able to move compounds rapidly through key development milestones and decision points, thus de-risking programs early in development. Prior to forming Drais, the management team founded AkaRx, Inc., successfully guiding their lead compound into Phase 2 proof of concept and negotiating an option and eventual sale of the company to Eisai Inc in 2010. As big